Average values at baseline for clinical and instrumental variables. Values are mean ± SD or n (%) unless otherwise specified.
| Clinical Variables | Total | ILO + BOSE | ILO | p |
|---|---|---|---|---|
| Age, yrs | 69 ± 12 | 66 ± 13 | 71 ± 11 | 0.46 |
| Sex, n | M = 4, F = 26 | M = 3, F = 12 | M = 1, F = 14 | 0.28 |
| dcSSc | 8/30 (26.66) | 8/15 (53.33) | 0/15 (0) | < 0.0001 |
| lcSSc | 22/30 (73.33) | 7/15 (46.66) | 15/15 (100) | |
| Anti-Scl70 | 8/30 (26.6) | 6/15 (40) | 2/15 (13.3) | < 0.0001 |
| Anticentromere | 17/30 (56.6) | 4/15 (26.6) | 13/15 (86.6) | < 0.0001 |
| Aspecific ANA | 5/30 (16.6) | 5/15 (33.3) | 0 | < 0.0001 |
| Average RP duration, yrs | 21 ± 12.3 | 18 ± 11 | 23 ± 13.3 | 0.29 |
| Average disease duration, yrs | 13 ± 8.5 | 14 ± 9.2 | 12 ± 7.88 | 0.85 |
| Capillaroscopic pattern | ||||
| Early | 6/15 | 2/15 | 4/15 | 0.65 |
| Active | 11/15 | 4/15 | 7/15 | 0.24 |
| Late | 13/15 | 9/15 | 4/15 | 0.13 |
| Instrumental Variables | ILO + BOSE vs ILO, Average Values at T0 | p |
|---|---|---|
| Season of test performance | 0.5 | |
| Spring | 4 vs 7 | |
| Summer | 1 vs 3 | |
| Autumn | 2 vs 1 | |
| Winter | 4 vs 4 | |
| Capillary absolute number | 6.8 ± 1.3 vs 7.1 ± 0.5 | 0.41 |
| FBP, PU | 59.74 ± 8.7 vs 86.59 ± 12 | 0.087 |
| FBP 36°C, PU | 96.47 ± 51 vs 136.9 ± 53 | 0.05 |
| ΔFBP, PU | 36.7 ± 30 vs 50.3 ± 29.7 | 0.16 |
| LASCA F, PU | 77.6 ± 42.6 vs 93.4 ± 34.6 | 0.48 |
| LASCA P, PU | 72.95 ± 48.5 vs 97.6 ± 36.6 | 0.15 |
ILO: iloprost; BOSE: bosentan; SSc: systemic sclerosis; dcSSc: diffuse cutaneous SSc; lcSSc: limited cutaneous SSc; ANA: antinuclear antibodies; RP: Raynaud phenomenon; FBP: fingertip blood perfusion; PU: perfusion units; LASCA: laser speckled contrast analysis.